普雷斯蒂奇消费保健

最新新闻

• 评级变动
  Oppenheimer Maintains Prestige Consumer Healthcare(PBH.US) With Buy Rating, Cuts Target Price to $72
  \u5e02\u573a\u8d44\u8baf · 2025/10/21
• Analysts Offer Insights on NA Companies: Springer Nature AG & Co. KGaA (OtherSPGDF) and Prestige Consumer Healthcare (PBH)
  TipRanks · 2026/8/6
• 评级变动
  Jefferies Maintains Prestige Consumer Healthcare(PBH.US) With Hold Rating, Cuts Target Price to $71
  \u5e02\u573a\u8d44\u8baf · 2025/10/27
• 评级变动
  RBC Capital Initiates Prestige Consumer Healthcare(PBH.US) With Buy Rating, Announces Target Price $129
  \u5e02\u573a\u8d44\u8baf · 2026/3/20
• 评级变动
  Research Alert: Pbh Q1: Revenue Up 25% To Cad2.1b On Stampede Deal; Maintains 2026 Guidance
  MT Newswires · 2026/5/7
• 评级变动
  CCORF Maintains Prestige Consumer Healthcare(PBH.US) With Buy Rating, Maintains Target Price $86
  \u5e02\u573a\u8d44\u8baf · 2026/3/23
• 评级变动
  Jefferies Maintains Prestige Consumer Healthcare(PBH.US) With Hold Rating, Cuts Target Price to $66
  \u5e02\u573a\u8d44\u8baf · 2026/1/31
• 评级变动
  Oppenheimer Maintains Prestige Consumer Healthcare(PBH.US) With Buy Rating, Announces Target Price $77
  \u5e02\u573a\u8d44\u8baf · 2026/2/11
• William Blair Maintains Prestige Consumer Healthcare(PBH.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Oppenheimer Downgrades Prestige Consumer Healthcare(PBH.US) to Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/14
• CCORF Maintains Prestige Consumer Healthcare(PBH.US) With Buy Rating, Maintains Target Price $72
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  Sidoti Upgrades Prestige Consumer Healthcare(PBH.US) to Buy Rating, Cuts Target Price to $80
  \u5e02\u573a\u8d44\u8baf · 2025/9/24
• 评级变动
  CCORF Maintains Prestige Consumer Healthcare(PBH.US) With Buy Rating, Cuts Target Price to $72
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  CCORF Maintains Prestige Consumer Healthcare(PBH.US) With Buy Rating, Cuts Target Price to $88
  \u5e02\u573a\u8d44\u8baf · 2025/11/7
• 评级变动
  Oppenheimer Maintains Prestige Consumer Healthcare(PBH.US) With Buy Rating, Announces Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  Oppenheimer Maintains Prestige Consumer Healthcare(PBH.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/2/24
• 评级变动
  CCORF Maintains Prestige Consumer Healthcare(PBH.US) With Buy Rating, Cuts Target Price to $86
  \u5e02\u573a\u8d44\u8baf · 2026/2/6
• 评级变动
  CCORF Maintains Prestige Consumer Healthcare(PBH.US) With Buy Rating, Maintains Target Price $88
  \u5e02\u573a\u8d44\u8baf · 2026/1/14
• Prestige Consumer Healthcare Inc. (PBH) Clear Eyes and Pillar5 Problems Drive Stock Lower, HBSS Investigating
  PR Newswire · 2026/6/25
• Premium Brands Holdings: Board Approves NCIB for Repurchase of Up to 1M Common Shares PBH.T
  Dow Jones · 2026/10/1

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。